Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224171 · ClinicalTrials.gov registry record · Phase 3
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
NCT01224171 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 416 participants.
The verdict
NCT01224171, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
Study Summary
This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
Interventions
- OTHER Placebo
- DRUG vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01224171
The ClinicalTrials.gov registry entry for NCT01224171 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01224171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01224171 about?
NCT01224171 is a clinical study titled "Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease". This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
What is the current status of trial NCT01224171?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2010-11. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01224171?
The interventions under investigation include: Placebo (OTHER), vedolizumab (DRUG).
Who is sponsoring clinical trial NCT01224171?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.